The safety of DTaP-HepB-IPV vaccine coadministered with PCV and Hib was compared with separate administration of DTaP, HepB, IPV, Hib, and PCV at 2, 4, and 6 months of age. Healthy 2-month-old infants (N=1008) were randomized to the two groups. Following dose 1, there was no significant difference between the groups in the incidence of fever >101.3 degrees F. After each dose, the incidence of any fever (> or =100.4 degrees F) was significantly higher in the Combination Vaccine Group. The rate of fever >103.1 degrees F was < or =1.4% in both groups after any of the doses. Medical advice visits for fever were infrequent in both groups (< or =1.2%). DTaP-HepB-IPV was safe and well tolerated when coadministered with PCV and Hib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2006.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.
View Article and Find Full Text PDFA Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts.
Circ Res
January 2025
Department of Health Development and Medicine (S.Y., H.H., J.S., S.B., H.N.), Osaka University Graduate School of Medicine, Japan.
Article Synopsis
- - The study focused on myofibroblasts and how a vaccine targeting fibroblast activation protein (FAP) might help reduce cardiac fibrosis in mice with chronic cardiac stress.
- - Mice were vaccinated with a FAP peptide while undergoing continuous treatment with angiotensin II and phenylephrine, resulting in a significant decrease in both cardiac fibrosis and the number of myofibroblasts.
- - The findings suggest that the FAP vaccine is a promising therapeutic option for cardiac fibrosis without causing harmful side effects in other injury models, indicating its potential for future treatments.
STING Nanoagonist Boosts Antitumor Immunity of Therapeutic DNA Vaccines.
Nano Lett
December 2024
Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai 200444, China.
Article Synopsis
- - Therapeutic DNA cancer vaccines stimulate immune responses but often fall short in effectiveness; researchers found that manganese-doped silica nanoparticles (MSNA) can enhance these vaccines' performance.
- - When combined with plasmid DNA encoding cancer antigens like α-fetoprotein, MSNA significantly increased specific immune responses in animal models, leading to better cancer immunity.
- - The study showed that MSNA not only improved T cell responses against cancer but also successfully prevented tumor growth in models for both liver and HPV-related cancers.
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
Lancet Infect Dis
November 2024
Moderna, Cambridge, MA, USA.
Background: Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high risk for severe respiratory disease. The RSV mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in the ConquerRSV trial in adults aged 60 years and older. We aimed to evaluate the safety and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine or SARS-CoV-2 mRNA vaccine.
View Article and Find Full Text PDFRandomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Postexposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand.
Open Forum Infect Dis
November 2024
Global Clinical Development Strategy, Sanofi, Marcy l'Étoile, France.
Background: A serum-free, highly purified Vero rabies vaccine-next generation (PVRV-NG2) is under development. We conducted a phase III trial to describe the safety and immunogenicity profile of PVRV-NG2 compared with those of licensed purified Vero rabies vaccine (PVRV) in a simulated rabies postexposure prophylaxis (PEP) Zagreb regimen in Thailand.
Methods: Healthy adults aged ≥18 years (n = 201) were randomized in a 2:1 ratio to receive PVRV-NG2 or PVRV in a rabies PEP Zagreb (days 0, 7, 21 [2-1-1]) regimen, with concomitant human rabies immunoglobulin (HRIG) at day 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!